Carregant...
The future of kinase inhibitors for DLBCL?
In this issue of Blood, Battistello et al present results exploring inhibition of signaling across key nodes in the B-cell receptor (BCR) signaling pathway for Bruton tyrosine kinase (BTK)-sensitive and BTK-insensitive diffuse large B-cell lymphoma (DLBCL).(1)
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5969385/ https://ncbi.nlm.nih.gov/pubmed/29794076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-841908 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|